— Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a loss of $67.2 million or $1.21 per share last year.
— Total revenues edged up to $6.01 million from $5.9 million in 2018
— Research and development expenses were almost unchanged year-over-year at $57.6 million in fiscal 2019
— Achieved progress in a focused discovery effort on follow-on compounds for the current HBV pipeline
— On track to advance a next-generation oral HBV specific RNA-destabilizer with chemical scaffolds distinct from AB-452 through lead optimization
— Ended 2019 with $90.8 million in cash, cash equivalents and short-term investments
— Expects to utilize between $54 to $58 million of cash and investments to fund operations in 2020
Most Popular
Lyft (LYFT) expects average ride volumes to improve through Q1 2021
Shares of Lyft Inc. (NASDAQ: LYFT) were up 8% in afternoon hours on Wednesday. The stock has gained 53% over the past 12 months and 25% since the beginning of
With new strategy in place, Target looks poised to tap growing online demand
Department store chain Target Corp. (NYSE: TGT), which has been thriving on the pandemic-driven shopping boom since early last year, maintained its strong performance during the holiday season and entered
Infographic: Dollar Tree’s (DLTR) performance in Q4
Dollar Tree (NYSE: DLTR) reported fourth-quarter financial results before the opening bell on Wednesday. The discount store reported a 7% increase in Q4 net sales to $6.7 billion. The company
